NCT06387173

Brief Summary

This study evaluates the side effects and outcomes of patients who undergo cryoablation for early stage breast cancer.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2

participants targeted

Target at below P25 for all trials

Timeline
885mo left

Started Jan 2024

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress3%
Jan 2024Jan 2099

Study Start

First participant enrolled

January 4, 2024

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

March 25, 2024

Completed
1 month until next milestone

First Posted

Study publicly available on registry

April 26, 2024

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 3, 2025

Completed
74 years until next milestone

Study Completion

Last participant's last visit for all outcomes

January 3, 2099

Expected
Last Updated

April 15, 2025

Status Verified

April 1, 2025

Enrollment Period

1 year

First QC Date

March 25, 2024

Last Update Submit

April 10, 2025

Conditions

Early Stage Breast Carcinoma

Outcome Measures

Primary Outcomes (1)

  • Prospectively track patients who undergo cryoablation for breast cancer and record post-treatment related events.

    record follow up of symptoms, reported complications, breast imaging findings, and results of any future biopsies related to cancer, and treatment of breast cancer.

    five years from last participant enrollment

Study Arms (1)

Observational

Patients have their medical records reviewed on study.

Other: Non-Interventional Study

Interventions

Non-Interventional StudyOTHER

Non-interventional study

Observational

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients undergoing cryoablation for breast cancer

You may qualify if:

  • Patients undergoing cryoablation for breast cancer

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UCLA / Jonsson Comprehensive Cancer Center

Los Angeles, California, 90095, United States

Location

Study Officials

  • Nimmi S Kapoor, MD

    UCLA / Jonsson Comprehensive Cancer Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 25, 2024

First Posted

April 26, 2024

Study Start

January 4, 2024

Primary Completion

January 3, 2025

Study Completion (Estimated)

January 3, 2099

Last Updated

April 15, 2025

Record last verified: 2025-04

Locations

US(1)